Alx Oncology Holdings Inc (ALXO) concluded trading on Thursday at a closing price of $1.42, with 2.64 million shares of worth about $3.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.18% during that period and on December 12, 2024 the price saw a loss of about -5.96%. Currently the company’s common shares owned by public are about 52.74M shares, out of which, 34.30M shares are available for trading.
Stock saw a price change of -21.55% in past 5 days and over the past one month there was a price change of 5.97%. Year-to-date (YTD), ALXO shares are showing a performance of -90.46% which decreased to -88.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.19 but also hit the highest price of $17.83 during that period. The average intraday trading volume for Alx Oncology Holdings Inc shares is 753.20K. The stock is currently trading -3.27% below its 20-day simple moving average (SMA20), while that difference is down -4.86% for SMA50 and it goes to -79.12% lower than SMA200.
Alx Oncology Holdings Inc (NASDAQ: ALXO) currently have 52.74M outstanding shares and institutions hold larger chunk of about 58.48% of that.
The stock has a current market capitalization of $74.89M and its 3Y-monthly beta is at 1.04. It has posted earnings per share of -$2.98 in the same period. It has Quick Ratio of 4.82 while making debt-to-equity ratio of 0.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALXO, volatility over the week remained 10.69% while standing at 9.76% over the month.
Stock’s fiscal year EPS is expected to rise by 26.31% while it is estimated to increase by 9.14% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on March 08, 2024 offering a Hold rating for the stock and assigned a target price range of between $10 and $14 to it. Coverage by Jefferies stated Alx Oncology Holdings Inc (ALXO) stock as a Buy in their note to investors on December 08, 2023, suggesting a price target of $18 for the stock. On December 22, 2021, Jefferies Downgrade their recommendations, while on September 30, 2021, Stifel Initiated their ratings for the stock with a price target of $106. Stock get an Outperform rating from Credit Suisse on May 05, 2021.
